<li>amobarbital<p>amobarbital will decrease the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment for ondansetron is recommended for patients on these drugs.</p></li><li>amphetamine<p>amphetamine increases toxicity of ondansetron by serotonin levels. Use Caution/Monitor. Closely monitor for signs and symptoms of serotonin syndrome (eg, agitation, tremor, tachycardia).</p></li><li>atazanavir<p>atazanavir will increase the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP-450 inhibitors may decrease clearance of ondansetron. However, no dosage adjustment for ondansetron is recommended.</p></li><li>bedaquiline<p>ondansetron and bedaquiline both increase  QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely</p></li><li>bosutinib<p>bosutinib increases levels of ondansetron by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>butabarbital<p>butabarbital will decrease the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment for ondansetron is recommended for patients on these drugs.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of ondansetron by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>carbamazepine will decrease the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>crizotinib<p>crizotinib increases levels of ondansetron by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>crofelemer<p>crofelemer increases levels of ondansetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.</p></li><li>dabrafenib<p>dabrafenib will decrease the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>daclatasvir<p>daclatasvir will increase the level or effect of ondansetron by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>darunavir<p>darunavir will increase the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP-450 inhibitors may decrease clearance of ondansetron. However, no dosage adjustment for ondansetron is recommended</p></li><li>deferasirox<p>deferasirox will decrease the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dexamethasone<p>dexamethasone will decrease the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment for ondansetron is recommended for patients on these drugs.</p></li><li>dichlorphenamide<p>dichlorphenamide and ondansetron both decrease  serum potassium. Use Caution/Monitor.</p></li><li>efavirenz<p>efavirenz will decrease the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>eliglustat<p>eliglustat increases levels of ondansetron by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of ondansetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.</p></li><li>fosamprenavir<p>fosamprenavir will increase the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP-450 inhibitors may decrease clearance of ondansetron. However, no dosage adjustment for ondansetron is recommended</p></li><li>goserelin<p>goserelin increases toxicity of ondansetron by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.</p></li><li>histrelin<p>histrelin increases toxicity of ondansetron by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.</p></li><li>hydroxyzine<p>hydroxyzine increases toxicity of ondansetron by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.</p></li><li>iloperidone<p>iloperidone increases levels of ondansetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.</p></li><li>indinavir<p>indinavir will increase the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP-450 inhibitors may decrease clearance of ondansetron. However, no dosage adjustment for ondansetron is recommended</p></li><li>isoniazid<p>isoniazid will increase the level or effect of ondansetron by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. CYP-450 inhibitors may decrease clearance of ondansetron. However, no dosage adjustment for ondansetron is recommended<span><br><br></span>isoniazid will increase the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP-450 inhibitors may decrease clearance of ondansetron. However, no dosage adjustment for ondansetron is recommended</p></li><li>itraconazole<p>itraconazole will increase the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP-450 inhibitors may decrease clearance of ondansetron. However, no dosage adjustment for ondansetron is recommended</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP-450 inhibitors may decrease clearance of ondansetron. However, no dosage adjustment for ondansetron is recommended</p></li><li>lenvatinib<p>ondansetron and lenvatinib both increase  QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.</p></li><li>leuprolide<p>leuprolide increases toxicity of ondansetron by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.</p></li><li>lomitapide<p>lomitapide increases levels of ondansetron by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Consider reducing dose when used concomitantly with lomitapide.</p></li><li>lopinavir<p>lopinavir and ondansetron both increase  QTc interval. Use Caution/Monitor.  Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.</p></li><li>mifepristone<p>mifepristone, ondansetron. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.</p></li><li>mitotane<p>mitotane decreases levels of ondansetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.</p></li><li>nafarelin<p>nafarelin increases toxicity of ondansetron by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.</p></li><li>nefazodone<p>nefazodone will increase the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP-450 inhibitors may decrease clearance of ondansetron. However, no dosage adjustment for ondansetron is recommended</p></li><li>nelfinavir<p>nelfinavir will increase the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP-450 inhibitors may decrease clearance of ondansetron. However, no dosage adjustment for ondansetron is recommended</p></li><li>norfloxacin<p>norfloxacin and ondansetron both increase  QTc interval. Use Caution/Monitor.  Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of ondansetron by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Paritaprevir and ritonavir inhibit P-gp. Caution if coadministered with P-gp substrates.</p></li><li>osimertinib<p>osimertinib and ondansetron both increase  QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.</p></li><li>oxcarbazepine<p>oxcarbazepine will decrease the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment for ondansetron is recommended for patients on these drugs.</p></li><li>panobinostat<p>ondansetron and panobinostat both increase  QTc interval. Modify Therapy/Monitor Closely. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended; however, antiemetic drugs known to prolong QTc (eg, dolasetron, granisetron, ondansetron) can be used with frequent ECG monitoring.</p></li><li>pasireotide<p>ondansetron and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>pentobarbital<p>pentobarbital will decrease the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment for ondansetron is recommended for patients on these drugs.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment for ondansetron is recommended for patients on these drugs.</p></li><li>phenytoin<p>phenytoin will decrease the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment for ondansetron is recommended for patients on these drugs.</p></li><li>ponatinib<p>ponatinib increases levels of ondansetron by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rifabutin<p>rifabutin will decrease the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>rifampin<p>rifampin will decrease the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ritonavir<p>ritonavir and ondansetron both increase  QTc interval. Use Caution/Monitor.  Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias. May increase ondansetron levels.</p></li><li>secobarbital<p>secobarbital will decrease the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment for ondansetron is recommended for patients on these drugs.</p></li><li>sorafenib<p>sorafenib and ondansetron both increase  QTc interval. Use Caution/Monitor.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>triptorelin<p>triptorelin increases toxicity of ondansetron by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.</p></li>